NHIQ · Nanthealth, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.47M | $17.26M | $17.05M | - | $16.63M | $16.50M | $16.37M | - | $14.36M | $16.09M |
| Cost of Revenue | $5.41M | $5.71M | $6.42M | - | $6.93M | $7.35M | $7.18M | - | $6.83M | $7.01M |
| Gross Profit | $7.06M | $11.55M | $10.63M | - | $9.71M | $9.15M | $9.19M | - | $7.53M | $9.08M |
| R&D | $2.36M | $6.66M | $5.16M | - | $6.30M | $5.86M | $5.71M | - | $4.65M | $4.85M |
| SG&A | $8.72M | $12.63M | $16.70M | - | $16.58M | $14.02M | $14.98M | - | $12.97M | $11.84M |
| Total Operating Expenses | $17.57M | $20.28M | $22.85M | - | $23.86M | $20.86M | $21.68M | - | $18.60M | $17.67M |
| D&A | $3.82M | $1.79M | $2.95M | - | $1.62M | $1.56M | $4.01M | - | $1.50M | $1.51M |
| Operating Income | ($10.51M) | ($8.73M) | ($12.23M) | - | ($14.16M) | ($11.71M) | ($12.49M) | - | ($11.07M) | ($8.59M) |
| Interest Expense | $3.49M | $3.47M | - | - | - | - | - | - | - | - |
| Income Tax | $54.0K | ($94.0K) | $74.0K | - | ($10.0K) | ($29.0K) | $20.0K | - | $23.0K | $6.0K |
| Net Income | ($14.99M) | ($17.48M) | ($12.24M) | - | ($13.66M) | ($12.51M) | ($15.95M) | - | ($10.84M) | ($15.30M) |
| EPS - Basic | ($1.00) | ($2.27) | ($1.59) | - | ($0.12) | ($0.11) | ($0.14) | - | ($0.09) | ($0.13) |
| EPS - Diluted | ($1.00) | ($2.27) | ($1.59) | - | ($0.12) | ($0.11) | ($0.14) | - | ($0.09) | ($0.13) |
Balance Sheet
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.82M | $6.17M | $14.15M | $1.76M | $635.0K | $5.71M | $16.08M | $29.08M | $45.51M | $51.99M |
| Accounts Receivable | - | - | $6.73M | $5.95M | $5.30M | $5.05M | $5.03M | - | $4.50M | $4.63M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | - | $9.76M | $10.41M | $6.22M | $4.85M | $5.29M | $3.20M | $2.07M | $2.32M |
| Current Assets | $15.34M | $14.99M | $24.71M | $12.59M | $12.15M | $14.86M | $26.13M | $39.41M | $56.80M | $61.26M |
| Total Assets | $146.48M | $157.42M | $169.50M | $159.55M | $160.91M | $166.89M | $181.40M | $197.83M | $217.37M | $225.28M |
| Current Liabilities | $191.09M | $59.21M | $38.39M | $35.63M | $33.59M | $23.59M | $25.01M | $27.95M | $34.56M | $29.57M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $396.66M | $410.65M | $406.14M | $384.94M | $362.07M | $354.99M | $358.00M | $359.82M | $364.16M | $361.38M |
| Stockholders' Equity | ($250.18M) | ($253.24M) | ($236.65M) | ($225.39M) | ($201.16M) | ($188.10M) | ($176.60M) | ($161.99M) | ($146.79M) | ($136.27M) |
| Retained Earnings | ($1.17B) | ($1.15B) | ($1.13B) | ($1.12B) | ($1.10B) | ($1.08B) | ($1.07B) | ($1.05B) | ($1.04B) | ($1.03B) |
Cash Flow
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($6.57M) | - | - | - | ($11.05M) | - | - | - |
| Investing Cash Flow | - | - | ($1.26M) | - | - | - | ($1.20M) | - | - | - |
| Financing Cash Flow | - | - | $20.60M | - | - | - | ($758.0K) | - | - | - |
| CapEx | - | - | $1.26M | - | - | - | $1.20M | - | - | - |
| Free Cash Flow | - | - | ($7.83M) | - | - | - | ($12.25M) | - | - | - |
Ratios
| Metric | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 56.6% | 66.9% | 62.3% | - | 58.3% | 55.5% | 56.2% | - | 52.4% | 56.4% |
| Operating margin | -84.3% | -50.6% | -71.7% | - | -85.1% | -71.0% | -76.3% | - | -77.1% | -53.4% |
| EBITDA margin | -53.7% | -40.2% | -54.4% | - | -75.4% | -61.5% | -51.8% | - | -66.6% | -44.0% |
| Net margin | -120.2% | -101.3% | -71.8% | - | -82.1% | -75.8% | -97.4% | - | -75.5% | -95.1% |
| Free cash flow margin | - | - | -46.0% | - | - | - | -74.8% | - | - | - |
| FCF / Net income | - | - | 0.64 | - | - | - | 0.77 | - | - | - |
| R&D / Revenue | 18.9% | 38.6% | 30.3% | - | 37.9% | 35.5% | 34.9% | - | 32.4% | 30.1% |
| SG&A / Revenue | 69.9% | 73.2% | 98.0% | - | 99.7% | 85.0% | 91.5% | - | 90.3% | 73.6% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -10.2% | -11.1% | -7.2% | - | -8.5% | -7.5% | -8.8% | - | -5.0% | -6.8% |
| Return on equity | 6.0% | 6.9% | 5.2% | - | 6.8% | 6.7% | 9.0% | - | 7.4% | 11.2% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.08 | 0.25 | 0.64 | 0.35 | 0.36 | 0.63 | 1.04 | 1.41 | 1.64 | 2.07 |
| Quick ratio | 0.08 | 0.25 | 0.64 | 0.35 | 0.36 | 0.63 | 1.04 | 1.41 | 1.64 | 2.07 |
| Cash ratio | 0.03 | 0.10 | 0.37 | 0.05 | 0.02 | 0.24 | 0.64 | 1.04 | 1.32 | 1.76 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -3.0x | -2.5x | - | - | - | - | - | - | - | - |
| Equity multiplier | -0.59 | -0.62 | -0.72 | -0.71 | -0.80 | -0.89 | -1.03 | -1.22 | -1.48 | -1.65 |
| Liabilities / Assets | 2.71 | 2.61 | 2.40 | 2.41 | 2.25 | 2.13 | 1.97 | 1.82 | 1.68 | 1.60 |
| Efficiency | ||||||||||
| Asset turnover | 0.09 | 0.11 | 0.10 | - | 0.10 | 0.10 | 0.09 | - | 0.07 | 0.07 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | 144d | - | 116d | 112d | 112d | - | 114d | 105d |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | 555d | - | 327d | 241d | 269d | - | 111d | 121d |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -25.0% | 4.6% | 4.1% | - | 15.8% | 2.5% | 1.3% | - | -23.5% | -8.5% |
| Revenue CAGR (3y) | -12.7% | -0.6% | -2.1% | - | -9.4% | -13.7% | -11.6% | - | -12.9% | -11.9% |
| Revenue CAGR (5y) | -10.5% | -6.0% | -5.2% | - | -5.2% | -8.9% | -6.2% | - | -10.8% | -12.6% |
| Gross profit growth (YoY) | -27.3% | 26.2% | 15.6% | - | 28.9% | 0.8% | 0.7% | - | -33.0% | -11.6% |
| Operating income growth (YoY) | 25.8% | 25.5% | 2.1% | - | -27.9% | -36.4% | -33.2% | - | -62.0% | -26.2% |
| Net income growth (YoY) | -9.7% | -39.7% | 23.3% | - | -26.0% | 18.2% | -3.5% | - | 1.4% | 68.3% |
| EPS growth (YoY) | -733.3% | -1963.6% | -1035.7% | - | -33.3% | 15.4% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | 36.1% | - | - | - | -13.1% | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -24.4% | -34.6% | -34.0% | -39.1% | -37.0% | -38.0% | -33.9% | -44.9% | -58.2% | -65.7% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$125.28M totalSoftware Related$62.63M · 50.0%
Software As AService$60.40M · 48.2%
Maintenance$1.72M · 1.4%
Professional Services$507.0K · 0.4%
Product And Service Other$23.0K · 0.0%
Peer comparison
Same SIC group: Services-Computer Processing & Data Preparation
Comparing NantHealth against the 5 most active filers in the same SIC group.